ATE550037T1 - Zusammensetzungen gegen das sars-coronavirus und ihre verwendungen - Google Patents
Zusammensetzungen gegen das sars-coronavirus und ihre verwendungenInfo
- Publication number
- ATE550037T1 ATE550037T1 AT05817101T AT05817101T ATE550037T1 AT E550037 T1 ATE550037 T1 AT E550037T1 AT 05817101 T AT05817101 T AT 05817101T AT 05817101 T AT05817101 T AT 05817101T AT E550037 T1 ATE550037 T1 AT E550037T1
- Authority
- AT
- Austria
- Prior art keywords
- sars coronavirus
- compositions against
- sars
- coronavirus
- compositions
- Prior art date
Links
- 241000315672 SARS coronavirus Species 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 241000711573 Coronaviridae Species 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62777304P | 2004-11-11 | 2004-11-11 | |
EP04105684 | 2004-11-11 | ||
EP04106192 | 2004-11-30 | ||
EP05102117 | 2005-03-17 | ||
EP05107288 | 2005-08-08 | ||
PCT/EP2005/055876 WO2006051091A1 (en) | 2004-11-11 | 2005-11-10 | Compositions against sars-coronavirus and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE550037T1 true ATE550037T1 (de) | 2012-04-15 |
Family
ID=35747767
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05817101T ATE550037T1 (de) | 2004-11-11 | 2005-11-10 | Zusammensetzungen gegen das sars-coronavirus und ihre verwendungen |
Country Status (9)
Country | Link |
---|---|
US (1) | US8106170B2 (de) |
EP (1) | EP1812067B1 (de) |
KR (1) | KR101255861B1 (de) |
AT (1) | ATE550037T1 (de) |
AU (1) | AU2005303758B2 (de) |
CA (1) | CA2582057C (de) |
NZ (1) | NZ553701A (de) |
SG (1) | SG159542A1 (de) |
WO (1) | WO2006051091A1 (de) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004009618A2 (en) | 2002-07-18 | 2004-01-29 | Crucell Holland B.V. | Recombinant production of mixtures of antibodies |
USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
NZ539813A (en) | 2002-12-17 | 2008-04-30 | Crucell Holland Bv | A replication defective recombinant adenovirus comprising a antigenic determinant of Plasmodium falciparum wherein the antigenic determinant is SEQ ID 6 |
US20100069614A1 (en) * | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
CA2527694C (en) | 2003-05-30 | 2015-07-14 | Hendricus Renerus Jacobus Mattheus Hoogenboom | Fab library for the preparation of anti vegf and anti rabies virus fabs |
CA2531684C (en) * | 2003-07-22 | 2014-03-11 | Crucell Holland B.V. | Binding molecules against sars-coronavirus and uses thereof |
ATE501171T1 (de) | 2004-05-27 | 2011-03-15 | Crucell Holland Bv | Bindungsmoleküle, die dazu fähig sind, das tollwutvirus zu neutralisieren, und anwendungen davon |
NZ553409A (en) * | 2004-10-12 | 2010-04-30 | Crucell Holland Bv | Binding molecules for treatment and detection of acute myeloid leukaemia |
PT1802336E (pt) * | 2004-10-14 | 2011-11-15 | Glaxosmithkline Biolog Sa | Vacinas de dose inicial/reforço para a malária |
US8052974B2 (en) | 2005-05-12 | 2011-11-08 | Crucell Holland B.V. | Host cell specific binding molecules capable of neutralizing viruses and uses thereof |
WO2007044695A2 (en) * | 2005-10-07 | 2007-04-19 | Dana-Farber Cancer Institute | ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF |
JP2009537143A (ja) | 2006-05-19 | 2009-10-29 | アムゲン インコーポレイティッド | Sarsコロナウイルスに対する抗体 |
CN101460519B (zh) * | 2006-06-06 | 2013-06-19 | 克鲁塞尔荷兰公司 | 具有杀灭葡萄球菌活性的人结合分子及其应用 |
EA017203B1 (ru) | 2006-09-07 | 2012-10-30 | Круселл Холланд Б.В. | Связывающие молекулы человека, способные нейтрализовать вирус гриппа h5n1, и их применение |
EP2242768A4 (de) * | 2008-01-17 | 2012-03-14 | Humabs Llc | Kreuzneutralisierung menschlicher monoklonaler antikörper gegen sars-cov und verfahren zu deren anwendung |
RU2505268C2 (ru) | 2008-06-30 | 2014-01-27 | Конинклейке Филипс Электроникс Н.В. | Спектральная компьютерная томография |
EP2374816B1 (de) * | 2010-04-07 | 2016-09-28 | Agency For Science, Technology And Research | Bindemoleküle gegen Chikungunya-Virus und Verwendungen davon |
US9441032B2 (en) | 2010-04-07 | 2016-09-13 | Agency For Science, Technology And Research | Binding molecules against Chikungunya virus and uses thereof |
CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
KR20230091201A (ko) | 2012-04-20 | 2023-06-22 | 메뤼스 엔.페. | Ig-유사 분자의 제조방법 및 제조수단 |
ZA201608812B (en) | 2014-06-26 | 2019-08-28 | Janssen Vaccines & Prevention Bv | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
WO2015197820A1 (en) | 2014-06-26 | 2015-12-30 | Crucell Holland B.V. | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
WO2021148884A1 (en) * | 2020-01-24 | 2021-07-29 | Tychan Pte. Ltd. | Anti-wuhan coronavirus antibodies |
WO2021156490A2 (en) | 2020-02-06 | 2021-08-12 | Vib Vzw | Corona virus binders |
AU2021227687B2 (en) | 2020-02-26 | 2023-02-23 | Vir Biotechnology, Inc. | Antibodies against SARS-CoV-2 and methods of using the same |
CN116096742A (zh) | 2020-03-09 | 2023-05-09 | 雅伯希勒拉生物公司 | 抗冠状病毒抗体及使用方法 |
WO2021201679A1 (en) | 2020-04-01 | 2021-10-07 | Kiadis Pharma Intellectual Property B.V. | Compositions and methods targeting coronaviruses |
WO2021205408A1 (en) * | 2020-04-10 | 2021-10-14 | Igy Immune Technologies And Life Sciences Inc. | Igy immunoglobulins targeting coronavirus, methods of preparing same, and methods of using same |
CA3175523A1 (en) | 2020-04-13 | 2021-10-21 | Antti Virtanen | Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample |
WO2021232041A1 (en) * | 2020-05-09 | 2021-11-18 | Baylor College Of Medicine | N-acetylcysteine and glycine for treatment of covid-19 and post covid-19 symptoms |
US20210346492A1 (en) | 2020-05-11 | 2021-11-11 | Janssen Pharmaceuticals, Inc. | SARS-CoV-2 Vaccines |
GB202007312D0 (en) * | 2020-05-18 | 2020-07-01 | Synthetic Vac Ltd | Mimotope peptides of the spike protein from the sars-cov-2 virus |
AU2021288203A1 (en) * | 2020-06-12 | 2023-01-19 | Vir Biotechnology, Inc. | Antibody therapies for SARS-CoV-2 infection |
CA3183367A1 (en) * | 2020-07-06 | 2022-01-13 | Gevorg GRIGORYAN | Antigen binding molecules targeting sars-cov-2 |
EP4188951A2 (de) * | 2020-07-27 | 2023-06-07 | IGM Biosciences, Inc. | Multimere coronavirus-bindende moleküle und verwendungen davon |
WO2022054068A1 (en) * | 2020-09-14 | 2022-03-17 | Ramot At Tel-Aviv University Ltd. | Antibodies for the prevention, treatment and detection of coronavirus infection |
EP3970798A1 (de) * | 2020-09-18 | 2022-03-23 | NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen | Sars-cov-2-nanokörper |
EP4217386A1 (de) * | 2020-09-24 | 2023-08-02 | The Broad Institute, Inc. | Zellfreie antikörper-engineering-plattform und neutralisierende antikörper für sars-cov-2 |
JP2023549677A (ja) * | 2020-11-06 | 2023-11-29 | チョ ファーマ インコーポレイテッド | 抗原およびその糖鎖操作抗体を含む免疫組成物 |
EP4271998A1 (de) | 2020-12-30 | 2023-11-08 | Abbott Laboratories | Verfahren zur bestimmung des sars-cov-2-antigens und anti-sars-cov-2-antikörpers in einer probe |
WO2023287324A1 (en) * | 2021-07-16 | 2023-01-19 | Joint Stock Company "Biocad" | Influenza virus-based isolated recombinant virus |
CN113908264B (zh) * | 2021-10-21 | 2023-06-23 | 中国人民解放军空军军医大学 | 基于噬菌体载体的新型冠状病毒疫苗及其制备方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL9101953A (nl) | 1991-11-21 | 1993-06-16 | Seed Capital Investments | Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen. |
US5624949A (en) | 1993-12-07 | 1997-04-29 | Eli Lilly And Company | Protein kinase C inhibitors |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
ES2190543T3 (es) | 1996-10-08 | 2003-08-01 | Bisys B V U | Procedimientos y sistemas que permiten seleccionar peptidos y proteinas que tienen una afinidad especifica respecto a un blanco. |
WO2000063403A2 (en) | 1999-04-15 | 2000-10-26 | Crucell Holland B.V. | Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein |
DE60209010T2 (de) | 2001-06-15 | 2006-09-28 | Crucell Holland B.V. | Chimäre phagen |
FR2828405B1 (fr) | 2001-08-09 | 2005-06-24 | Virbac Sa | Vaccin anti-coronavirus |
EP1633775A2 (de) | 2003-06-13 | 2006-03-15 | Crucell Holland B.V. | Antigene peptide des sars-coronavirus und anwendungen davon |
WO2005012337A2 (en) | 2003-07-15 | 2005-02-10 | Crucell Holland B.V. | Antigenic peptides of sars coronavirus and uses thereof |
EP1646645A1 (de) | 2003-07-21 | 2006-04-19 | Crucell Holland B.V. | Antigene peptide des sars-coronavirus und anwendungen davon |
CA2531684C (en) | 2003-07-22 | 2014-03-11 | Crucell Holland B.V. | Binding molecules against sars-coronavirus and uses thereof |
US7396914B2 (en) | 2003-08-04 | 2008-07-08 | University Of Massachusetts | SARS nucleic acids, proteins, antibodies, and uses thereof |
WO2005060520A2 (en) * | 2003-11-25 | 2005-07-07 | Dana-Farber Cancer Institute, Inc. | ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF |
-
2005
- 2005-11-10 US US11/667,640 patent/US8106170B2/en not_active Expired - Fee Related
- 2005-11-10 WO PCT/EP2005/055876 patent/WO2006051091A1/en active Application Filing
- 2005-11-10 CA CA2582057A patent/CA2582057C/en not_active Expired - Fee Related
- 2005-11-10 NZ NZ553701A patent/NZ553701A/xx not_active IP Right Cessation
- 2005-11-10 SG SG201000925-6A patent/SG159542A1/en unknown
- 2005-11-10 AU AU2005303758A patent/AU2005303758B2/en not_active Ceased
- 2005-11-10 AT AT05817101T patent/ATE550037T1/de active
- 2005-11-10 EP EP05817101A patent/EP1812067B1/de active Active
- 2005-11-10 KR KR1020077009194A patent/KR101255861B1/ko not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR101255861B1 (ko) | 2013-04-17 |
CA2582057C (en) | 2015-08-11 |
AU2005303758B2 (en) | 2011-04-28 |
EP1812067A1 (de) | 2007-08-01 |
NZ553701A (en) | 2009-12-24 |
US8106170B2 (en) | 2012-01-31 |
US20080014204A1 (en) | 2008-01-17 |
AU2005303758A1 (en) | 2006-05-18 |
SG159542A1 (en) | 2010-03-30 |
KR20070083768A (ko) | 2007-08-24 |
WO2006051091A1 (en) | 2006-05-18 |
EP1812067B1 (de) | 2012-03-21 |
CA2582057A1 (en) | 2006-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE550037T1 (de) | Zusammensetzungen gegen das sars-coronavirus und ihre verwendungen | |
ATE449097T1 (de) | Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer | |
ECSP088107A (es) | Inhibidores de la proteasa ns3 del vhc | |
CY1111050T1 (el) | Φωσφονικα, μονοφωσφοναμιδικα, διφωσφοναμιδικα για την αγωγη των ιϊκων παθησεων | |
WO2008127364A3 (en) | Antiviral compounds and use thereof | |
WO2008051477A3 (en) | Hcv ns3 protease inhibitors | |
CR20150058A (es) | Inhibidores de la proteasa ns3 del hcv | |
EA201000777A1 (ru) | Ингибиторы репликации вируса иммунодефицита человека | |
WO2008057208A3 (en) | Hcv ns3 protease inhibitors | |
WO2008051514A3 (en) | Hcv ns3 protease inhibitors | |
WO2008051475A3 (en) | Hcv ns3 protease inhibitors | |
EA201100084A1 (ru) | Сшиваемая полимерная композиция | |
EA201000494A1 (ru) | Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4 | |
BRPI0608604B8 (pt) | moduladores de 2,3-dioxigenase de indolamina e composição farmacêutica | |
WO2007133865A3 (en) | Hcv/hiv inhibitors an their uses | |
BRPI0818672A2 (pt) | 2'-fluor-2'-desoxitetra-hidrouridinas como inibidores da citidina desaminase | |
BRPI0612124A2 (pt) | derivados de heteroarila para o tratamento de viroses | |
NO20070751L (no) | Inhibitorer av HCV-replifikasjon | |
EA200900781A1 (ru) | 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды | |
NO20084637L (no) | Cyklopropyl-kondenserte indolobenzaepin HCV NS5B inhibitorer | |
NO20082298L (no) | Kaliumkanalinhibitorer | |
EA201270630A1 (ru) | Гетероциклические сетр ингибиторы | |
EA200601889A1 (ru) | Лечение инфекционных заболеваний | |
ATE417849T1 (de) | Pyrazoloä4,3-düpyrimidine | |
WO2010053573A3 (en) | Screen for inhibitors of filovirus and uses therefor |